Journal of the American College of Cardiology
Volume 47, Issue 8, Supplement, 18 April 2006, Pages C19-C31
ViewpointC-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
Under an Elsevier user license
open archive
Abbreviations and Acronyms
ACS
acute coronary syndrome
apo
apolipoprotein
CAD
coronary artery disease
CETP
cholesterol ester transfer protein
ELISA
enzyme-linked immunoabsorbent assay
HDL-C
high-density lipoprotein cholesterol
HOCl
hypochlorous acid
hs-CRP
high-sensitivity C-reactive protein
LDL-C
low-density lipoprotein cholesterol
Lp(a)
lipoprotein (a)
Lp-PLA2
lipoprotein-associated phospholipase A2
MPO
myeloperoxidase
OR
odds ratio
OxLDL
oxidized LDL
OxPLs
oxidized phospholipids
PAF-AH
platelet-activating factor acetylhydrolase
PCI
percutaneous coronary intervention
Cited by (0)
Drs. Tsimikas and Ridker are supported in part by funds from the Donald W. Reynolds Foundation, Las Vegas, Nevada. Potential conflicts of interest: Dr. Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease. Dr. William A. Zoghbi acted as guest editor.
Copyright © 2006 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.